CCM
ANIP icon

Cullen Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Cullen Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,113
Closed -$355K – 213
2023
Q3 		$355K Sell
6,113
-6,323
-51% -$365K ﹤0.01% 161
2023
Q2 		$669K Buy
12,436
+2,231
+22% +$98.9K 0.01% 213
2023
Q1 		$405K Buy
+10,205
New +$430K ﹤0.01% 227
2022
Q4 		– Sell
-13,709
Closed -$441K – 202
2022
Q3 		$441K Buy
13,709
+3,086
+29% +$106K ﹤0.01% 222
2022
Q2 		$315K Buy
+10,623
New +$306K ﹤0.01% 247

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cullen Capital Management's ANIP Position: Q4 2023 in Review

Cullen Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 6,113 shares — an estimated $355K sold.

Cullen Capital Management first reported a position in ANIP in Q2 2022 and held it in 5 quarters. The position peaked at $669K in Q2 2023. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • Cullen Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cullen Capital Management sold 6,113 ANI Pharmaceuticals shares in Q4 2023, an estimated $355K.
  • Cullen Capital Management first reported a position in ANI Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Cullen Capital Management's ANI Pharmaceuticals position peaked at $669K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Cullen Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.